CMS confirmed that the Medicare GLP-1 Bridge launches July 1, 2026, and runs through December 31, 2026. For a $50 monthly copay, eligible Part D beneficiaries will get access to all formulations of Wegovy and Foundayo, plus the Zepbound KwikPen, administered through Humana’s LI NET infrastructure. The Bridge is the transition to the BALANCE Model, which begins in participating Part D plans in January 2027 and in opt-in state Medicaid programs as early as May 2026.
Medicare’s entry into anti-obesity drug coverage is the first federal validation of GLP-1 reimbursement at scale for a non-diabetic indication. That shifts both PBM negotiating posture for the commercial book and the baseline utilization assumption that self-insured employer health plans have been pricing into their specific and aggregate stop-loss programs.
Who It Affects
Self-insured employer health plans, Taft-Hartley funds, and public-entity health programs that cover GLP-1s for obesity under commercial formularies, or that are currently excluding or tightly gating them. Mid-to-large employers with a meaningful Medicare-age retiree population sitting in a wrap around a Part D plan have a second layer of exposure, since the Bridge interacts with secondary coverage. Captives writing medical stop-loss on employer groups sit in the same line of fire on attachment adequacy.
The Reserve Mechanism
The dominant effect is a frequency increase on Rx claims flowing through a shift in the expected claim ratio (ECR) for the pharmacy component of self-funded health plan IBNR. Employees who see a parent, spouse, or sibling access GLP-1s at a $50 Medicare copay will pressure benefits committees on commercial access, and plans that had been counting on utilization management to hold utilization below the prescribing-eligible population will see that ceiling lift. Severity per claim is more ambiguous. Medicare’s list price discipline pressures commercial WAC over time, but rebate pass-through under the Consolidated Appropriations Act of 2026 unwinds the historical spread, so the net-cost trajectory depends on plan-specific contract mechanics.
The secondary effect is on specific stop-loss attachment adequacy. Attachment points set during 2024 and 2025 renewals were calibrated against GLP-1 utilization rates of 2 percent to 5 percent of the obese-eligible population. If the Bridge and BALANCE rollouts push commercial utilization into the 8 percent to 12 percent band, more claimants cross the specific attachment on cumulative annual Rx spend alone, which moves Bornhuetter-Ferguson and expected-claims estimates for the net layer. Stop-loss carriers are repricing GLP-1 lasering provisions and tightening attachment definitions at renewal; plans that accept a laser trade a lower premium for a higher effective retention on the highest-utilizing claimants, and the reserve has to reflect the new retention.
A third effect is regulatory. The Mental Health Parity and Addiction Equity Act non-quantitative treatment limitation framework can be invoked where a plan caps GLP-1 access for obesity while covering other chronic-disease drugs without comparable gating. The Morgan Lewis analysis of ADA implications for obesity as a protected condition compounds this. Plans with restrictive GLP-1 policies may need to post a contingent reserve for benefit-design litigation exposure separate from the pharmacy claim reserve itself.
What to Ask Your Actuary
- What share of our 2026 Rx trend assumption is attributable to GLP-1 utilization, and how sensitive is the ECR for the pharmacy component to a 20 percent increase in eligible-member uptake over the second half of the year?
- If our specific stop-loss carrier proposes a GLP-1 laser at the next renewal, what is the breakeven cost-share design, and how should the net IBNR change to reflect the higher effective retention on lasered claimants?
- Are our IBNR lag factors for Rx claims still appropriate given the prescription-to-fill-to-PBM-settlement lag on specialty submissions, or do we need to separate GLP-1s into their own development segment?
What to Watch Next
CMS Part D plan participation announcements for the BALANCE Model, expected in Q3 2026, will signal how much commercial PBM pricing leverage actually materializes in 2027 contracts. A broad participation roster pulls commercial WAC down faster; a narrow one leaves the Bridge as a six-month pilot with limited spillover. Also watch the KFF tracker on state Medicaid opt-in decisions and any final DOL guidance tying GLP-1 coverage to ERISA fiduciary duties, both of which will tighten the link between plan-design choices and the contingent reserve line.